Skip to main content
    T

    Teva Pharma Industries Ltd ADR (TEVA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE

    $41.12
    +0.40 (+0.98%)

    Market Cap: $47.49B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    77%(30/39)
    Avg Surprise
    +37.69%
    Streak
    9 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.73
    Range$0.60 - $0.89
    8 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.00n/a
    30d ago$0.00n/a
    7d ago$0.72+1.1%
    Current$0.73
    Revenue Consensus
    $4.2B
    Range$4.0B - $4.4B
    11 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.84
    Range$0.62 - $1.65
    11 analysts
    Revenue Consensus
    $4.6B
    Range$4.3B - $5.4B
    13 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.84---
    Sep 26EST
    		-$0.73---
    Jun 26
    Reported Jul 29
    		$0.64$0.05+1180.00%Beat-3.0%
    Mar 26
    Reported Apr 29
    		$0.53$0.46+15.22%Beat+1.9%
    Dec 25
    Reported Jan 28
    		$0.96$0.64+50.00%Beat+35.2%
    Sep 25
    Reported Nov 5
    		$0.75$0.66+13.64%Beat+8.7%
    Jun 25
    Reported Jul 30
    		$0.66$0.62+6.45%Beat+8.2%
    Mar 25
    Reported May 7
    		$0.52$0.46+13.04%Beat+8.3%
    Dec 24
    Reported Jan 29
    		$0.71$0.70+1.43%Beat-29.0%
    Sep 24
    Reported Nov 6
    		$0.69$0.66+4.55%Beat+15.0%
    Jun 24
    Reported Jul 31
    		$0.61$0.55+10.91%Beat+8.9%
    Mar 24
    Reported May 8
    		$0.48$0.51-5.88%Miss+20.0%
    Dec 23
    Reported Jan 31
    		$1.00$0.76+31.58%Beat+40.8%
    Sep 23
    Reported Nov 8
    		$0.60$0.61-1.64%Miss+1.7%
    Jun 23
    Reported Aug 2
    		$0.56$0.53+5.66%Beat-17.6%
    Mar 23
    Reported May 10
    		$0.40$0.55-27.27%Miss-27.3%
    Dec 22
    Reported Feb 8
    		$0.71$0.71+0.00%Beat-7.8%
    Sep 22
    Reported Nov 3
    		$0.59$0.62-4.84%Miss+0.0%
    Jun 22
    Reported Jul 26
    		$0.68$0.56+21.43%Beat+15.3%
    Mar 22
    Reported May 3
    		$0.55$0.55+0.00%Beat-12.7%
    Dec 21
    Reported Feb 9
    		$0.77$0.73+5.48%Beat+13.2%
    Sep 21
    Reported Oct 27
    		$0.59$0.65-9.23%Miss+1.7%
    Jun 21
    Reported Jul 28
    		$0.59$0.59+0.00%Beat+7.3%
    Mar 21
    Reported Apr 28
    		$0.63$0.60+5.00%Beat-17.1%
    Dec 20
    Reported Feb 10
    		$0.68$0.62+9.68%Beat+9.7%
    Sep 20
    Reported Nov 5
    		$0.58$0.58+0.00%Beat+0.0%
    Jun 20
    Reported Aug 5
    		$0.55$0.53+3.77%Beat-8.3%
    Mar 20
    Reported May 7
    		$0.76$0.59+28.81%Beat+26.7%
    Dec 19
    Reported Feb 12
    		$0.62$0.61+1.64%Beat+17.0%
    Sep 19
    Reported Nov 7
    		$0.58$0.59-1.69%Miss-14.7%
    Jun 19
    Reported Aug 7
    		$0.60$0.58+3.45%Beat-23.1%
    Mar 19
    Reported May 2
    		$0.60$0.58+3.45%Beat-36.2%
    Dec 18
    Reported Feb 13
    		$0.53$0.55-3.64%Miss-43.0%
    Sep 18
    Reported Nov 1
    		$0.68$0.54+25.93%Beat-32.0%
    Jun 18
    Reported Aug 2
    		$0.78$0.64+21.88%Beat-23.5%
    Mar 18
    Reported May 3
    		$0.94$0.67+40.30%Beat-11.3%
    Dec 17
    Reported Feb 8
    		$0.93$0.76+22.37%Beat-32.6%
    Sep 17
    Reported Nov 2
    		$1.00$1.03-2.91%Miss-
    Jun 17
    Reported Aug 3
    		$1.02$1.06-3.77%Miss-
    Mar 17
    Reported May 11
    		$1.06$1.03+2.91%Beat-
    Dec 16
    Reported Feb 13
    		$1.38$1.35+2.22%Beat-

    Dividends

    Dividend Metrics

    Forward Yield0.00%
    Forward Annual Dividend$0.00
    Payout Ratio0.00%
    FrequencyQuarterly
    No dividend payments in the selected period.

    Key Metrics

    Valuation
    P/E Ratio14.28EV/EBITDA23.71x
    Price/FCF36.03xFCF Yield2.78%
    Profitability
    Profit Margin4.08%Operating Margin4.03%
    ROE9.69%ROIC6.48%
    Financial Health
    Debt/Equity2.14xInterest Coverage1.78x
    Current Ratio0.88xQuick Ratio0.67x
    Trading Statistics
    Beta0.82Avg Volume6.32M
    52-Week High$42.0252-Week Low$18.83

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$40.21
    SMA 20$39.83
    SMA 50$38.13
    SMA 200$34.10
    EMA 10$40.41
    EMA 20$39.77
    EMA 50$38.18
    EMA 200$33.36

    MACD

    Line: 0.85Signal: 0.79Hist: 0.06

    ADX

    ADX: 32.9+DI: 24.9-DI: 12.5

    Aroon & PSAR

    Aroon Up84.0
    Aroon DownN/A
    PSAR$38.54

    Bollinger Bands

    Upper Band$41.46
    Lower Band$38.21
    %B Position817%(Upper)
    Band Width0.90

    RSI (14-Day)

    Neutral
    63.4

    Momentum Oscillators

    Stoch %K73.7
    Stoch %D75.2
    Williams %R-23.9
    ROC (10d)4.6%
    Momentum1.81
    CCI (20d)148.6
    MFI (14d)63.2

    Volatility Measures

    ATR (14d)$1.19(2.9%)
    StdDev (20d)0.81
    Hist Vol28.4%(Moderate)

    Volume Flow

    VWAP$41.33
    OBV421.0M
    AD Line212.8M
    CMF (20d)-0.048

    Volume Metrics

    Avg Vol (20d)6.4M
    Vol Ratio1.4x
    VWMA (20d)$40.06

    Pivot Points

    R3$42.65
    R2$42.26
    R1$41.49
    Pivot Point$41.10
    S1$40.33
    S2$39.94
    S3$39.17

    Advanced Oscillators

    TSI22.19
    Ultimate Osc54.1
    KST61.10

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$4.14B$3.98B$4.71B$4.48B$4.18B$3.89B$4.23B$4.33B$4.16B$3.82B$4.46B$3.85B
    Cost of Revenue$1.99B$2.01B$2.06B$2.18B$2.07B$2.01B$2.11B$2.18B$2.14B$2.05B$2.04B$2.00B
    Gross Profit$2.15B$1.97B$2.66B$2.30B$2.10B$1.88B$2.12B$2.15B$2.02B$1.77B$2.42B$1.85B
    Operating Expenses$2.00B$1.32B$2.35B$1.42B$1.65B$1.36B$2.15B$2.20B$2.03B$1.99B$1.66B$1.51B
    R&D$250.00M$222.00M$267.00M$256.00M$244.00M$247.00M$271.00M$240.00M$269.00M$242.00M$234.00M$253.00M
    SG&A$317.00M$304.00M$367.00M$317.00M$305.00M$297.00M$302.00M$298.00M$283.00M$278.00M$292.00M$268.00M
    Operating Income$149.00M$652.00M$300.00M$882.00M$455.00M$519.00M$-29,000,000$-51,000,000$-5,000,000$-218,000,000$756.00M$344.00M
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$200.00M$201.00M$292.00M$209.00M$203.00M$225.00M$763.00M$272.00M$241.00M$250.00M$260.00M$280.00M
    Income Before Tax$-455,000,000$436.00M$91.00M$648.00M$204.00M$294.00M$-247,000,000$-321,000,000$-244,000,000$-471,000,000$508.00M$64.00M
    Income Tax Expense$121.00M$67.00M$-390,000,000$214.00M$-78,000,000$74.00M$28.00M$69.00M$630.00M$-52,000,000$41.00M$-12,000,000
    Net Income$-576,000,000$369.00M$480.00M$433.00M$282.00M$214.00M$-217,000,000$-437,000,000$-846,000,000$-139,000,000$463.00M$69.00M
    EBITDA$-19,000,000$877.00M$632.00M$1.10B$657.00M$953.00M$1.16B$207.00M$246.00M$55.00M$1.52B$627.00M
    EBIT$-260,000,000$638.00M$372.00M$855.00M$406.00M$709.00M$893.00M$-52,000,000$-13,000,000$-217,000,000$1.25B$344.00M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TEVA

    News

    Teva Pharmaceutical Industries (NYSE:TEVA) Given New $47.00 Price Target at Barclays

    Barclays has raised its price target for Teva Pharmaceutical Industries (NYSE:TEVA) to $47.00 from $42.00, maintaining an "overweight" rating and suggesting a 13.24% upside. The company has a consensus "Moderate Buy"...

    MarketBeat•10/15/26•Bullish

    TEVA Maintained by Barclays -- Price Target Raised to $47.00

    Barclays has maintained its Overweight rating on Teva Pharmaceutical Industries Ltd (TEVA) and raised its price target from $42.00 to $47.00. Despite this optimistic analyst outlook...

    GuruFocus•10/15/26•Somewhat-Bearish

    Teva to Host R&D Day on Wednesday, November 11 in New York City

    Teva Pharmaceutical Industries Ltd. announced it will host an R&D Day on November 11, 2026, in New York City. The event will focus on the company's R&D pipeline, near-term value creation potential...

    GlobeNewswire•10/13/26•Somewhat-Bullish

    Teva Pharmaceutical Industries Ltd. to Host R&D Day on November 11, 2026

    Teva Pharmaceutical Industries Ltd. announced it will host an R&D Day on November 11, 2026, in New York to discuss its R&D pipeline, value creation potential...

    Quiver Quantitative•10/12/26•Neutral

    Teva to Host R&D Day on Wednesday, November 11 in New York City

    Teva Pharmaceutical Industries Ltd. announced it will host an R&D Day on Wednesday, November 11, 2026, in New York City. The event will showcase Teva's R&D pipeline, its potential for near-term value creation...

    GlobeNewswire•10/12/26•Somewhat-Bullish

    TEVA Valuation and Fair Value

    P/E
    14.3x
    Forward P/E
    7.0x
    EV/EBITDA
    23.7x
    P/FCF
    36.0x
    PEG
    1.3x
    P/B
    6.3x
    See GNG's fair value

    TEVA Profitability: Margins, ROIC and FCF

    Gross margin
    52.5%
    Operating margin
    4.0%
    Net margin
    4.1%
    ROIC
    6.5%
    ROE
    9.7%
    FCF margin
    7.8%
    FCF yield
    2.8%

    TEVA Competitors

    CompanyTicker
    Veeva Systems Inc Class AVEEV
    IQVIA Holdings IncIQV
    Agilent Technologies IncA
    Waters CorporationWAT
    Edwards Lifesciences CorpEW
    Haleon plcHLN
    argenx NV ADRARGX
    Revolution Medicines IncRVMD

    Sector: Healthcare

    TEVA Analyst Ratings

    Consensus
    Buy
    Analysts
    8
    Strong Buy
    3
    Buy
    4
    Hold
    1
    Sell
    0
    Strong Sell
    0

    TEVA Bull Case vs Bear Case

    Bull case

    • TEVA beat EPS estimates in 100.0% of its last 8 reported quarters.
    • 87.5% of TEVA's analyst ratings are Buy or Strong Buy.

    Bear case

    • TEVA's quarterly revenue changed -0.8% year over year.
    • TEVA has a debt-to-equity ratio of 2.1x.

    TEVA Earnings: Beat Rate and Next Report

    Beat rate
    8 of 8 quarters (100.0%)
    Average surprise
    160.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.73
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    TEVA Dividend

    Forward yield
    0.0%
    Payout ratio
    0.0%

    Frequently Asked Questions About TEVA

    Does TEVA pay dividends?

    Teva Pharma Industries Ltd ADR (TEVA) has a dividend payment track record. See the TEVA dividend history page for its current payment status, TTM yield, and recorded payments.

    What is TEVA's P/E ratio?

    Teva Pharma Industries Ltd ADR has a price-to-earnings (P/E) ratio of 14.28.

    What is TEVA's market cap?

    Teva Pharma Industries Ltd ADR (TEVA) has a market capitalization of $47.49B with a current stock price of $41.12.

    Related stocks

    Sector: Healthcare

    All stocks starting with T

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In